Literature DB >> 19120293

Update on worldwide efforts to prevent type 1 diabetes.

Jay S Skyler1.   

Abstract

This paper reviews worldwide efforts to interdict the type 1 diabetes (T1D) disease process, during the stage of evolution of the disease prior to the time of disease onset. The goal of intervention before disease onset is to arrest immune destruction and thus prevent or delay clinical disease. In this regard, there have been several large-scale multicenter randomized controlled clinical trials designed to prevent T1D. These have tested nicotinamide, parenteral insulin, oral insulin, nasal insulin, and the elimination of cow's milk from infant feeding.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19120293      PMCID: PMC2928677          DOI: 10.1196/annals.1447.055

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  7 in total

1.  Intervening before the onset of Type 1 diabetes: baseline data from the European Nicotinamide Diabetes Intervention Trial (ENDIT).

Authors: 
Journal:  Diabetologia       Date:  2003-02-27       Impact factor: 10.122

2.  Effects of insulin in relatives of patients with type 1 diabetes mellitus.

Authors: 
Journal:  N Engl J Med       Date:  2002-05-30       Impact factor: 91.245

3.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.

Authors:  Bart Keymeulen; Evy Vandemeulebroucke; Anette G Ziegler; Chantal Mathieu; Leonard Kaufman; Geoff Hale; Frans Gorus; Michel Goldman; Markus Walter; Sophie Candon; Liliane Schandene; Laurent Crenier; Christophe De Block; Jean-Marie Seigneurin; Pieter De Pauw; Denis Pierard; Ilse Weets; Peppy Rebello; Pru Bird; Eleanor Berrie; Mark Frewin; Herman Waldmann; Jean-François Bach; Daniel Pipeleers; Lucienne Chatenoud
Journal:  N Engl J Med       Date:  2005-06-23       Impact factor: 91.245

4.  Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.

Authors:  Jay S Skyler; Jeffrey P Krischer; Joseph Wolfsdorf; Catherine Cowie; Jerry P Palmer; Carla Greenbaum; David Cuthbertson; Lisa E Rafkin-Mervis; H Peter Chase; Ellen Leschek
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

5.  Islet autoantibodies, nationality and gender: a multinational screening study in first-degree relatives of patients with Type I diabetes.

Authors:  A J K Williams; P J Bingley; W P T Moore; E A M Gale
Journal:  Diabetologia       Date:  2002-02       Impact factor: 10.122

6.  Study design of the Trial to Reduce IDDM in the Genetically at Risk (TRIGR).

Authors: 
Journal:  Pediatr Diabetes       Date:  2007-06       Impact factor: 4.866

7.  European Nicotinamide Diabetes Intervention Trial (ENDIT): a randomised controlled trial of intervention before the onset of type 1 diabetes.

Authors:  E A M Gale; P J Bingley; C L Emmett; T Collier
Journal:  Lancet       Date:  2004-03-20       Impact factor: 79.321

  7 in total
  26 in total

Review 1.  Insulin as a key autoantigen in the development of type 1 diabetes.

Authors:  Maki Nakayama
Journal:  Diabetes Metab Res Rev       Date:  2011-11       Impact factor: 4.876

Review 2.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

Review 3.  Oral tolerance.

Authors:  Howard L Weiner; Andre Pires da Cunha; Francisco Quintana; Henry Wu
Journal:  Immunol Rev       Date:  2011-05       Impact factor: 12.988

Review 4.  Oral tolerance.

Authors:  Ana M C Faria; Howard L Weiner
Journal:  Immunol Rev       Date:  2005-08       Impact factor: 12.988

Review 5.  Emerging Concepts on Disease-Modifying Therapies in Type 1 Diabetes.

Authors:  Carla Greenbaum; Sandra Lord; Dana VanBuecken
Journal:  Curr Diab Rep       Date:  2017-10-17       Impact factor: 4.810

Review 6.  Primary and secondary prevention of Type 1 diabetes.

Authors:  J S Skyler
Journal:  Diabet Med       Date:  2013-02       Impact factor: 4.359

7.  Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.

Authors:  Diane K Wherrett; Brian Bundy; Dorothy J Becker; Linda A DiMeglio; Stephen E Gitelman; Robin Goland; Peter A Gottlieb; Carla J Greenbaum; Kevan C Herold; Jennifer B Marks; Roshanak Monzavi; Antoinette Moran; Tihamer Orban; Jerry P Palmer; Philip Raskin; Henry Rodriguez; Desmond Schatz; Darrell M Wilson; Jeffrey P Krischer; Jay S Skyler
Journal:  Lancet       Date:  2011-06-27       Impact factor: 79.321

8.  The Juvenile Diabetes Research Foundation at forty: updates of research in type 1 diabetes.

Authors:  Concepcion R Nierras; Mark A Atkinson; Robert A Goldstein
Journal:  Diabetes       Date:  2010-07       Impact factor: 9.461

9.  In vivo islet protection by a nuclear import inhibitor in a mouse model of type 1 diabetes.

Authors:  Daniel J Moore; Jozef Zienkiewicz; Peggy L Kendall; Danya Liu; Xueyan Liu; Ruth Ann Veach; Robert D Collins; Jacek Hawiger
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

10.  Regulatory T cell phenotype and function 4 years after GAD-alum treatment in children with type 1 diabetes.

Authors:  M Pihl; L Akerman; S Axelsson; M Chéramy; M Hjorth; R Mallone; J Ludvigsson; R Casas
Journal:  Clin Exp Immunol       Date:  2013-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.